Another recent study showed a very low response rate of NPM1-mut MDS patients to hypomethylating agents, while NPM1-mut sAMLs treated with intensive chemotherapy showed a high rate of complete responses with 39% of patients undergoing allogeneic SCT [72]. Here, NPM1 is linked to myelodysplastic syndrome.